Matribhumi Samachar English
Management to host conference call at 8:00 AM Eastern time on Friday, June 26, 2026 Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – June 25, 2026) – Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s fourth fiscal quarter …
Read More »Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – June 16, 2026) – Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26, 2026 to discuss Medexus’s results for its fourth fiscal quarter and fiscal year ended March 31, 2026. Medexus …
Read More »Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
UM171 Cell Therapy is conditionally approved in Europe as Zemcelpro® (dorocubicel) Securing Canadian rights to a proprietary advanced clinical-stage product candidate developed in Canada adds to Medexus’s medium-term product pipeline and helps build a North American allo-HSCT franchise Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – June 9, 2026) – Medexus …
Read More »Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – April 15, 2026) – Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercialization of GRAFAPEX™ (treosulfan) for Injection in the United States and on certain recent capital allocation and capital structure developments and announced company management’s …
Read More »